ClinicalTrials.gg
CompletedNCT01421121Updated Nov 27, 2012

Safety and Immunogenicity of an Inactivated EV71 Vaccine in Infants

A Phase 2 interventional study of 100U EV71 vaccine with adjuvant and 200 U EV71 vaccine with adjuvant in Infection, Viral, Enterovirus, sponsored by Sinovac Biotech Co., Ltd. Completed at 1 site in China. Open to participants aged 6 Months to 35 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2012-11-27.

Sponsored by Sinovac Biotech Co., Ltd · Phase 2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
540
Allocation
Randomized
Ages
6 Months to 35 Months
Sex
All
01

Study summary

A randomized, placebo-controlled, double-blind clinical trial is to evaluate the safety and immunogenicity of a new inactivated EV71 vaccine developed by Sinovac Biotech CO., LTD.

02

Conditions studied

  • Infection, Viral, Enterovirus
03

In context

Infections

2,096 studies on the registry are indexed under Infections; 364 are open to participants now.

This study's enrollment of 540 is above the median of 113 across 1,305 interventional studies indexed under Infections.

Browse Infections studies →

Lead sponsor

Sinovac Biotech Co., Ltd is the lead sponsor of 93 studies on the registry; 18 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Months to 35 Months
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy males and females, aged from 6 months to 11 years old Health is determined by medical history, physical examination, laboratory examination and clinical judgment of the investigator
  2. Provided legal identification for the sake of recruitment.
  3. Subjects and/or parent(s)/legal guardian(s) are able to understand and sign informed consents.
  4. Birth weight more than 2500 grams

Exclusion criteria

Exclusion Criteria:

  1. History of Hand-foot-mouth Disease
  2. Subject that has allergic history of vaccine, or allergic to any ingredient of vaccine
  3. Serious adverse reactions to vaccines such as anaphylaxis, hives, respiratory difficulty, angioedema, or abdominal pain
  4. Congenital malformations or developmental disorders, genetic defects, or severe malnutrition
  5. Epilepsy, seizures or convulsions history, or family history of mental illness
  6. disease or immunodeficiency, or parents, brothers and sisters have autoimmune diseases or immunodeficiency
  7. History of asthma, angioedema, diabetes or
  8. History of thyroidectomy or thyroid disease that required medication within the past 12 months
  9. Bleeding disorder diagnosed by a doctor (e.g. factor deficiency, coagulopathy, or disorder requiring special precautions) or significant bruising or bleeding difficulties with IM injections or blood draws
  10. Asplenia, functional asplenia or any condition resulting in the absence or removal the spleen
  11. Acute illness or acute exacerbation of chronic disease within the past 7 days
  12. Any history of medications or cytotoxic medications or inhaled within the past six months (with the exception of corticosteroid nasal spray for allergic rhinitis or topical corticosteroids for an acute uncomplicated dermatitis)
  13. History of any blood products within 3 months
  14. Administration of any within 28 days
  15. Administration of subunit or inactivated vaccines ,e.g., pneumococcal vaccine, or allergy treatment within 14 days
  16. Axillary temperature > 37.0 centigrade before vaccination
  17. Abnormal laboratory parameters before vaccination
  18. Any medical, psychiatric, social condition, occupational reason or other responsibility that, in the judgment of the investigator, is a to protocol participation or impairs a volunteer's ability to give
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
540 participants (actual)

Study arms

  • Experimental
    100U EV71 vaccine with adjuvant

    120 infants received 2 doses of 100U EV71 vaccine with aluminium hydroxide adjuvant 28 days apart

    Biological: 100U EV71 vaccine with adjuvant

  • Experimental
    200 U EV71 vaccine with adjuvant

    120 infants received 2 doses of 200U EV71 vaccine with aluminium hydroxide adjuvant 28 days apart

    Biological: 200 U EV71 vaccine with adjuvant

  • Experimental
    400U EV71 vaccine with adjuvant

    120 infants received 2 doses of 400U EV71 vaccine with aluminium hydroxide adjuvant 28 days apart

    Biological: 400U EV71 vaccine with adjuvant

  • Experimental
    200U EV71 vaccine without adjuvant

    60 infants received 2 doses of 200U EV71 vaccine without adjuvant 28 days apart

    Biological: 200U EV71 vaccine without adjuvant

  • Placebo comparator
    Placebo

    120 infants received 2 doses of placebo 28 days apart.

    Biological: Placebo

Interventions

  • Biological100U EV71 vaccine with adjuvant

    Drug page: Enterovirus 71 vaccine

    inactivated vaccine (vero cell) against EV71 of 100U /0.5ml, two doses, 28 days interval

    Also known as: EV71 vaccine

  • Biological200 U EV71 vaccine with adjuvant

    Drug page: Enterovirus 71 vaccine

    inactivated vaccine (vero cell) against EV71 of 200U /0.5ml, two doses, 28 days interval

    Also known as: EV71 vaccine

  • Biological400U EV71 vaccine with adjuvant

    Drug page: Enterovirus 71 vaccine

    inactivated vaccine (vero cell) against EV71 of 400U /0.5ml, two doses, 28 days interval

    Also known as: EV71 vaccine

  • inactivated vaccine (vero cell) against EV71 without adjuvant of 200U /0.5ml, two doses, 28 days interval

    Also known as: EV71 vaccine

  • BiologicalPlacebo

    0.5ml placebo, two doses, 28 days interval

06

What researchers measure

Primary outcomes

  1. Neutralization antibody geometric mean titer in infants 28 days after immunization with EV71 vaccine with or without aluminium hydroxide adjuvant

    Primary immunogenicity end point were geometric mean titer of neutralization antibody againt EV71 virus \>= 1:8

    Time frame: 6 month

Secondary outcomes

  1. The rates and severity of solicited adverse events in infants following immunization as a Measure of Safety and Tolerability

    solicited local adverse events include Pain, Redness, Swelling, Induration, Rash, Pruritus at injection site. solicited general adverse events include Fever, Nausea, Vomiting, Diareahhea, Decreased appetite, Be agitated (irritability, abnormal crying), fatigue, allergy

    Time frame: 6 months

07

Study locations

1 site
  • GuangXi Center for Diseases Control and Prevention
    Nanning, Guangxi, China
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2011, a primary completion of Sep 2011 and a completion of Dec 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 22, 2011
First posted
Aug 22, 2011
Start
Jun 2011
Primary completionActual
Sep 2011
CompletionActual
Dec 2011
Last update
Nov 27, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 27, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01421121
Responsible party
Sponsor
First posted
Aug 22, 2011
Start date
Jun 2011
Primary completion
Sep 2011
Completion
Dec 2011
Last update
Nov 27, 2012

Study contacts

Yan-pin Li, MD
principal investigator · Guangxi Centers for Disease Control and Prevention

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Enterovirus 71 vaccine

Start the discussion